Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
April 12, 2017Recent hospitalization is a risk factor for further suicide attempts -- potentially related to patient care perceptionsWILMINGTON, Del. - NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental...
-
March 24, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 24, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
March 19, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 20, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
February 10, 2017Company developing NRX-101 – first potential treatment for Acute Suicidal Ideation in Bipolar Depression
Wilmington, Delaware & Tel Aviv, Israel , Feb. 10, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today...
-
January 4, 2017Clinical stage biopharma company advances development of first-in-class drug to decrease the risk of suicide in those suffering from bipolar depression
Biotech Showcase at the JP Morgan Healthcare Conference NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB) in Bipolar...
Click here to view our corporate presentation or on the image below
 |
